← FDA DRUG APPROVALS

FDA ANDA · ANDA090291

CEFEPIME HYDROCHLORIDE

Sponsor: CHARTWELL RX

APPLICATION
ANDA090291
TYPE
ANDA
ORIGINAL APPROVAL
2010-12-21
LATEST ACTION
2017-08-15
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CEFEPIME HYDROCHLORIDEDiscontinued
CEFEPIME HYDROCHLORIDE EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
CEFEPIME HYDROCHLORIDEDiscontinued
CEFEPIME HYDROCHLORIDE EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
CEFEPIME HYDROCHLORIDEDiscontinued
CEFEPIME HYDROCHLORIDE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2017-08-15Labeling · Supplement 2 · standardAP
2010-12-21OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →